# Decheng Capital

> Decheng Capital is a VC fund backing Biotechnology and Health Care. See 103 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Menlo Park, United States
- Total investments: 103
- Last investment: Apr 2026
- Lead investor: 39%
- Fund size: $650M
- Last fund: Dec 2020
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/decheng-capital-/about/
- Website: https://www.decheng.com

Decheng Capital is an investment firm that provides capital and strategic support to life science companies with revolutionary technologies and growth-stage healthcare companies with a strong market presence. It is a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successfulcompanies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of the healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.

## Contacts

5 contacts available for Decheng Capital. Shizune tracks 6 team members at Decheng Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/decheng-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $8M–$126M |
| Series B | $15M–$150M |
| Series C | $22M–$255M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 47 | 46% |
| Health Care | 41 | 40% |
| Medical | 20 | 19% |
| Pharmaceutical | 15 | 15% |
| Biopharma | 14 | 14% |

28 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 26 | 25% |
| Series A | 25 | 24% |
| Series C | 20 | 19% |
| Funding Round | 6 | 6% |
| Series D | 5 | 5% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 43 | 42% |
| China | 19 | 18% |
| Canada | 1 | 1% |
| Singapore | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dan Zabrowski | Venture Partner | 0 | https://shizune.co/investors/profile/dan-zabrowski |
| Min Cui | Founder and Managing Director | 12 | https://shizune.co/investors/profile/min-cui |
| Dayton Misfeldt | Partner | 4 | https://shizune.co/investors/profile/dayton-misfeldt |
| Nathan Pliam | Partner | 4 | https://shizune.co/investors/profile/nathan-pliam |
| Victor Tong | Partner | 6 | https://shizune.co/investors/profile/victor-tong |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Microtide Biotechnology | Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine. | $7.3M | Series A | Apr 29, 2026 |  |
| Syneron | Syneron was founded by Sinovation Ventures and is dedicated to using artificial intelligence and biotechnology to address two significant global challenges: the efficient development of novel biological therapies and the low-carbon manufacture of biochemicals. | $150M | Series B | Mar 31, 2026 |  |
| Polares Medical | Polares medical is a medical device company with a novel device for treating mitral valve regurgitation. | $50M | Series C | Mar 03, 2026 |  |
| Cellares | Cellares develops and operates integrated technologies for automated cell therapy manufacturing and quality control that help biopharmaceutical partners scale development to industrial production. The company’s offerings include the Cell Shuttle platform for end-to-end automation of the cell therapy manufacturing process and the Cell Q platform forautomated quality control, supported by integrated software and consumable cartridges. Cellares positions itself as an Integrated Development and Manufacturing Organization that supports process transfer, scalable production, and regulatory pathways for clinical and commercial programs. Its services enable clients to transition manual processes onto automated systems and expand manufacturing capacity to meet broader patient demand. | $257M | Series D | Jan 28, 2026 |  |
| Phrontline Biopharma | Phrontline Biopharma specializes in the development of ADC to address unmet medical needs in the field of oncology. | $60M | Seed | Nov 21, 2025 |  |
| Excellergy | Excellergy develops portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe allergic diseases. | $70M | Series A | Oct 13, 2025 |  |
| YolTech Therapeutics | Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease. | $42.1M | Series B | Sep 11, 2025 |  |
| Ottimo Pharma | Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden. | $140M | Series A | Dec 19, 2024 |  |
| Aclaris Therapeutics | Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical andaesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist. | $80M | Post-IPO Equity | Nov 18, 2024 |  |
| Medtech Technology | Medtech Technology is a firm that develops innovative ophthalmic medical devices.It has developed its own artificial lens production and research technology platform, as well as a technological barrier to high-end artificial lens manufacture. | $28.2M | Series B | Sep 14, 2024 |  |

10 of 103 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 13 deals together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 11 deals together
- [NFX](https://shizune.co/investors/profile/nfxcapital) — VC Fund, 7 deals together
- [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital) — VC Fund, 7 deals together
- [Longitude Capital](https://shizune.co/investors/profile/longitude-capital) — VC Fund, 6 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 6 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Asia](https://shizune.co/investors/biotechnology-investors-asia)
- [Biotechnology VC Funds in Asia](https://shizune.co/investors/biotechnology-vc-funds-asia)
- [Biotech Investors in Asia](https://shizune.co/investors/biotech-investors-asia)
- [Biotech VC Funds in Asia](https://shizune.co/investors/biotech-vc-funds-asia)
- [Biotechnology Investors in China](https://shizune.co/investors/biotechnology-investors-china)
- [Biotechnology VC Funds in China](https://shizune.co/investors/biotechnology-vc-funds-china)

## FAQ

### What does Decheng Capital invest in?

Decheng Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 103 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Decheng Capital's check size?

Decheng Capital typically joins rounds of $8M–$126M at Series A, $15M–$150M at Series B and $22M–$255M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Decheng Capital participates in.

### How do I contact Decheng Capital?

Public channels for Decheng Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Decheng Capital?

The team at Decheng Capital includes Dan Zabrowski (Venture Partner), Min Cui (Founder and Managing Director) and Dayton Misfeldt (Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co